Shopping Cart
Remove All
Your shopping cart is currently empty
Ligelizumab (QGE 031) is a high-affinity humanized anti-IgE monoclonal antibody suitable for research related to chronic spontaneous urticaria.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $247 | - | In Stock | |
| 5 mg | $647 | - | In Stock | |
| 10 mg | $987 | - | In Stock | |
| 25 mg | $1,460 | - | In Stock | |
| 50 mg | $1,970 | - | In Stock |
| Description | Ligelizumab (QGE 031) is a high-affinity humanized anti-IgE monoclonal antibody suitable for research related to chronic spontaneous urticaria. |
| In vivo | Ligelizumab (10 μg, intraperitoneal injection) can completely protect mice from antigen-induced systemic anaphylaxis in a passive systemic anaphylaxis model in transgenic mice expressing human FcεRIα. [1] |
| Synonyms | QGE 031, Anti-IGHE Recombinant Antibody |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | < 1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID |
| Cas No. | 1322627-61-1 |
| Color | Transparent |
| Appearance | Liquid |
| Storage | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.